Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Docetaxel

Cisplatin

Immunomodulating Agents

Immunologic Factors

Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy

Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy

Anlotinib 8mg qd po. Taking anlotinib daily for 2 weeks and stop for 1 week.

Anlotinib

Chemotherapy

Thoracic radiotherapy was delivered using the daily image-guided intensity modulated radiation therapy (IMRT) technique. The total radiation dose was 66-68 Gy to the gross tumor in 17-22 daily fractions.

Radiotherapy

consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)

Immunotherapy

Hui Liu, Professor

This is a prospective, randomized, controlled phase II clinical study for evaluating anlotinib combined with concurrent chemoradiotherapy followed by consolidation immunotherapy versus concurrent chemoradiotherapy followed by consolidation immunotherapy in locally advanced, unresectable NSCLC.

This is a prospective, randomized, controlled phase II clinical study for evaluating anlotinib combined with concurrent chemoradiotherapy followed by consolidation immunotherapy versus concurrent chemoradiotherapy followed by consolidation immunotherapy in locally advanced, unresectable NSCLC. In this study, the enrolled patients were divided into the experimental group and the control group at a ratio of 1:1. The patients in the experimental group received anlotinib combined with curative concurrent chemoradiotherapy first, while the patients in the control group received curative concurrent chemoradiotherapy. Those who are evaluated as CR, PR or SD after the aforementioned treatment will enter consolidation immunotherapy. Patients will receive tislelizumab 200mg iv. drip, Q3W, for up to 12 months.

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Evaluating Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy Versus Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer: A Prospective, Randomized Controlled Phase II Clinical Trial

From the first day of treatment to the day of progression or the day of death.

It was calculated from the first day of treatment to the day of death.

The proportion patients evaluated for CR and PR

Adverse effects are graded according to the CTCAE 5.0 version, including multiple organs and tissues, such as gastrointestinal disease and symptom, cardiovascular disease, respiratory diseases and so on.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer	NCT05481775	Locally Advance... Efficacy and Sa...	Anlotinib Chemotherapy Radiotherapy Immunotherapy	18 Years - 75 Years	Sun Yat-sen University
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer	NCT05481775	Locally Advance... Efficacy and Sa...	Anlotinib Chemotherapy Radiotherapy Immunotherapy	18 Years - 75 Years	Sun Yat-sen University
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer	NCT05481775	Locally Advance... Efficacy and Sa...	Anlotinib Chemotherapy Radiotherapy Immunotherapy	18 Years - 75 Years	Sun Yat-sen University

Spots Global Cancer Trial Database for anlotinib combined with chemoradiotherapy